Ionis Pharmaceuticals (IONS) Stock Analysis & AI Equity Report
Ionis Pharmaceuticals (IONS) overview
Ionis Pharmaceuticals (IONS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 944m and operating profit of USD -382m; the year-end share price was 79.11 USD and market capitalisation was USD 12,919m. Ionis Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ionis Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Ionis Pharmaceuticals
Ionis Pharmaceuticals discovers and develops RNA-targeted medicines for serious diseases and sells or partners on medicines across multiple markets. Its marketed medicines address conditions including familial chylomicronemia syndrome, hereditary angioedema, transthyretin amyloidosis, spinal muscular atrophy, and amyotrophic lateral sclerosis. Ionis independently commercializes some products, co-commercializes others with partners, and licenses or distributes additional medicines through collaborators.
Generate the Ionis Pharmaceuticals report
Ionis Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ionis Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Ionis Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.